TherapeuticsMD, Inc.
TXMD
$1.10
$0.01991.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 156.93% | 53.54% | 35.25% | -97.70% | -98.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 156.93% | 53.54% | 35.25% | -97.70% | -98.57% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 156.93% | 53.54% | 35.25% | -97.70% | -98.57% |
| SG&A Expenses | -20.92% | -37.19% | -46.71% | -69.94% | -81.53% |
| Depreciation & Amortization | -64.17% | -54.18% | -44.79% | 76.09% | 46.54% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.89% | -39.32% | -46.53% | -65.22% | -78.74% |
| Operating Income | 60.16% | 55.23% | 59.03% | -109.39% | -114.91% |
| Income Before Tax | 87.55% | 64.72% | 69.74% | -109.48% | -116.76% |
| Income Tax Expenses | -46.51% | -46.51% | 27.91% | -- | -- |
| Earnings from Continuing Operations | 88.75% | 65.49% | 69.97% | -109.38% | -116.61% |
| Earnings from Discontinued Operations | 106.79% | 103.22% | 105.08% | -97.50% | -109.18% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.46% | 71.66% | 78.78% | -104.85% | -114.24% |
| EBIT | 60.16% | 55.23% | 59.03% | -109.39% | -114.91% |
| EBITDA | 63.09% | 58.75% | 63.10% | -108.20% | -113.10% |
| EPS Basic | 92.81% | 73.85% | 81.12% | -104.00% | -112.41% |
| Normalized Basic EPS | 53.57% | 68.87% | 73.14% | -104.44% | -108.12% |
| EPS Diluted | 91.82% | 73.30% | 81.25% | -104.73% | -116.25% |
| Normalized Diluted EPS | 53.57% | 68.87% | 73.14% | -105.16% | -110.00% |
| Average Basic Shares Outstanding | 3.09% | 6.10% | 10.58% | 13.65% | 15.73% |
| Average Diluted Shares Outstanding | 3.09% | 6.10% | 10.58% | 9.95% | 11.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |